-
Zenas Biopharma (ZBIO) PT Lowered to $43 at Citi
-
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
-
Citi Reiterates Buy Rating on Zenas Biopharma (ZBIO)
-
Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences
-
Citi Starts Zenas Biopharma (ZBIO) at Buy
-
Zenas BioPharma Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Initial Public Offering
-
Zenas BioPharma (ZBIO) Prices Upsized 13.24M Share IPO at $17/sh
-
Zenas BioPharma Announces Pricing of Upsized Initial Public Offering

